Contrast CT, PET/CT assess cancer therapy for melanoma
Dynamic contrast-enhanced CT and FDG-PET/CT can provide additional information to evaluate and confirm how well melanoma patients respond to immune-modulated and antiangiogenic cancer therapy, according to researchers from Dana-Farber Cancer Institute.
The group performed FDG-PET/CT and CT perfusion imaging scans in a phase I clinical trial of the use of bevacizumab plus ipilimumab to treat patients with unresectable stage III or IV melanoma. The researchers found that patients with FDG-PET/CT images showing partial metabolic response achieved longer disease-free survival than those with stable metabolic disease or progressive metabolic disease.
New Data Shows Decline in Medical Imaging Utilization
A new analysis of Medicare data finds that spending on medical imaging continues to decline and that Medicare patients are receiving fewer imaging procedures. Learn More
MITA Now Includes Radiopharmaceutical Industry in Membership
With new membership MITA unites both halves of nuclear medicine. Learn More
CT Lung Cancer Screening Named Top Five Advance in 2011
The American Society of Clinical Oncology (ASCO) named CT-based lung cancer screening amongst 2011’s top five advances in its annual report on progress against cancer. Learn More
- © 2012 National Electrical Manufacturers Association |
- Privacy Policy |
- Terms & Conditions